New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 24, 2014
08:08 EDTNVS, MMMEMA committee recommends approval for 3M rivastigmine patch
The EMA's Committee for Medicinal Products for Human Use adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Rivastigmine transdermal patches intended for symptomatic treatment of mild to moderately severe Alzheimer's dementia. The applicant for this medicinal product is 3M Health Care (MMM). Rivastigmine 3M Health Care Ltd is a generic of Novartis' (NVS) Exelon.
News For MMM;NVS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
December 17, 2014
08:42 EDTMMM3M Company price target raised to $190 from $164 at BofA/Merrill
BofA/Merrill raised 3M Company price target to $190 following the better than expected dividend raise, rising margins, and incremental M&A in 2015-16. Shares are Buy rated.
07:29 EDTNVSFDA PDUFA Date for Novartis Bexsero is December 17, 2014
Subscribe for More Information
December 16, 2014
08:52 EDTMMM3M Company says on track to deliver 2013-2017 financial objectives
Says will increase R&D investment, productivity. Says healthcare business is fastest-growing business unit. Comments taken from 3M Company's 2015 Outlook Meeting.
08:47 EDTNVSHemispherx Ampligen provides anti-tumor activity
Subscribe for More Information
07:39 EDTMMM3M Company says adjusting 2013-2017 share buyback plan to $20B-$22B
Subscribe for More Information
07:06 EDTNVSBioLineRx and Novartis enter into strategic collaboration agreement
Subscribe for More Information
06:10 EDTMMM3M Company raises Q1 dividend by 20% to $1.03 per share
The board of 3M declared a dividend on the companyís common stock of $1.03 per share for the Q1, a 20% increase over the quarterly dividend paid in 2014. The dividend is payable Mar. 12, 2015, to shareholders of record at the close of business on Feb. 13, 2015.
06:08 EDTMMM3M Company backs long-term EPS objective of up 9%-11% per year
Subscribe for More Information
06:06 EDTMMM3M Company sees FY15 EPS $8.00-$8.30, consensus $8.20
Subscribe for More Information
05:48 EDTNVSNovartis gains FDA approval for Signifor LAR
Subscribe for More Information
December 15, 2014
08:31 EDTMMM3M Company to sell Static Control business to Desco Industries
3M announced that it has signed an agreement with Desco Industries for Desco to purchase the assets of 3Mís global Static Control business. 3M's Static Control business is a provider of products and solutions that help prevent, detect, and protect against Electrostatic Discharge events. The transaction is expected to close during the first quarter of 2015 after the successful completion of Descoís financing and is subject to customary closing conditions. Terms of the transaction were not disclosed. 3Mís Static Control business has annual global sales of about $45M. The business employs approximately 150 people worldwide, with manufacturing operations in Sanford, N.C. Substantially all of these employees are expected to transfer to Desco.
December 12, 2014
08:36 EDTNVSNovartis reports BOLERO-1 trial did not meet primary objective
Subscribe for More Information
05:31 EDTNVSNovartis reports Cosentyx 'superior' in head-to-head psoriasis study
Subscribe for More Information
December 11, 2014
08:29 EDTMMM3M Company December volatility elevated into 2015 Outlook Meeting
3M Company December call option implied volatility is at 22, January and April is at 17; compared to its 26-week average of 17 according to Track Data, suggesting large near term price movement into its 2015 Outlook Meeting on December 16.
06:55 EDTMMM3M Company to host 2015 outlook meeting
Subscribe for More Information
December 10, 2014
09:02 EDTMMM3M Company, Whitepeaks Dental Solutions settle dental ceramics coloring suit
Subscribe for More Information
December 8, 2014
13:07 EDTNVSNovartis announces data from Jakavi trial
Novartis (NVS) announced data from the largest clinical trial of myelofibrosis patients treated with Jakavi, supporting the safety profile and efficacy benefit as measured in primary and secondary endpoints respectively. In an analysis of 1,144 patients treated with Jakavi to date in this ongoing expanded access study, 69% of patients achieved >50% reduction in spleen size from baseline and patients also experienced a clinically meaningful improvement in myelofibrosis symptom score, important treatment goals for patients with myelofibrosis. Findings from the study were presented at the 56th Annual Meeting of the American Society of Hematology in San Francisco, California. Novartis research and development efforts, in collaboration with Incyte Corporation (INCY), include early-phase and post-marketing studies in myelofibrosis and other myeloproliferative neoplasms. More than 50 abstracts on ruxolitinib are being presented at ASH, including three oral presentations exploring combinations of ruxolitinib with various investigational compounds, evaluating the possibility of simultaneously targeting multiple cancer pathways that may be involved in the pathogenesis of myelofibrosis. The JUMP study is a Phase IIIb, expanded-access trial for countries with no access to Jakavi outside of a clinical trial. The open-label, multicenter study analyzed 1,144 enrolled myelofibrosis patients who received daily starting doses of either 5 mg, 15 mg or 20 mg of Jakavi twice daily based on platelet counts at baseline. The primary endpoint is assessment of safety and tolerability of Jakavi. Overall, the safety and efficacy profile of Jakavi was consistent with previous studies.
13:05 EDTNVSNovartis reports six-year results from Phase III ENESTnd study
Subscribe for More Information
11:30 EDTNVSLeerink generics pharmaceutical analyst holds analyst/industry conference call
Subscribe for More Information
05:42 EDTNVSSandoz Phase III data shows filgrastim has similar safety, efficacy as NEUPOGEN
Sandoz, a Novartis (NVS) company, announced Phase III data that demonstrated similarity of its investigational biosimilar filgrastim compared to the US-licensed reference product, Amgen's (AMGN) NEUPOGEN in the prevention of severe neutropenia in patients with breast cancer receiving neoadjuvant myelosuppressive chemotherapy. The study also showed that repeated switching at each cycle between the investigational biosimilar and the originator filgrastim showed no impact on efficacy, safety or immunogenicity. The PIONEER study was a Phase III study designed to compare the efficacy and safety of the investigational biosimilar and the reference product with respect to mean duration of severe neutropenia following Cycle 1 chemotherapy. PIONEER was a randomized, double-blind, four-group, multi-center non-inferiority trial conducted at 27 centers. The trial randomized 218 breast cancer patients receiving neoadjuvant myelosuppressive chemotherapy.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use